Literature DB >> 16820421

Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress.

D Aarsland1, K Brønnick, U Ehrt, P P De Deyn, S Tekin, M Emre, J L Cummings.   

Abstract

OBJECTIVE: To explore the profile of neuropsychiatric symptoms in patients with dementia associated with Parkinson's disease (PDD).
METHODS: 537 patients with PDD drawn from an international multicentre clinical trial of rivastigmine were assessed using the 10-item Neuropsychiatric Inventory (NPI). A cluster analysis was used to investigate the inter-relationship of NPI items. Associations between the clusters and demographic and clinical variables were analysed.
RESULTS: 89% of the patients presented at least one symptom on the NPI, 77% had two or more symptoms and 64% had at least one symptom with a score > or = 4. The most common symptoms were depression (58%), apathy (54%), anxiety (49%) and hallucinations (44%). Patients with more severe dementia and advanced Parkinson's disease had more neuropsychiatric symptoms. Nearly 60% of the care givers reported at least one NPI symptom to be of at least moderate severe distress. Five NPI clusters were identified: one group with few and mild symptoms (52%); a mood cluster (11%, high scores on depression, anxiety and apathy); apathy (24%; high apathy and low scores on other items); agitation (5%, high score on agitation and high total NPI score); and a psychosis cluster (8%; high scores on delusions and hallucinations). The psychosis and agitation clusters had the lowest Mini-Mental State Examination score and the highest Unified Parkinson's Disease Rating Scale and care giver distress scores.
CONCLUSION: Neuropsychiatric symptoms are common in patients with PDD. The profile of these symptoms differs from that in other types of dementia. Subgroups with different neuropsychiatric profiles were identified. These subgroups may be associated with distinct neurobiological changes, which should be explored in future studies.

Entities:  

Mesh:

Year:  2006        PMID: 16820421      PMCID: PMC2117797          DOI: 10.1136/jnnp.2005.083113

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  36 in total

1.  Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease.

Authors:  S Tekin; M S Mega; D M Masterman; T Chow; J Garakian; H V Vinters; J L Cummings
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

2.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

3.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

4.  Mental symptoms in Parkinson's disease are important contributors to caregiver distress.

Authors:  D Aarsland; J P Larsen; K Karlsen; N G Lim; E Tandberg
Journal:  Int J Geriatr Psychiatry       Date:  1999-10       Impact factor: 3.485

5.  Neuropsychological profile of patients with Parkinson's disease without dementia.

Authors:  Carmen Janvin; Dag Aarsland; Jan P Larsen; Kenneth Hugdahl
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

6.  Evidence for impaired encoding and retrieval memory profiles in Parkinson disease.

Authors:  Daniel Weintraub; Paul J Moberg; William C Culbertson; John E Duda; Matthew B Stern
Journal:  Cogn Behav Neurol       Date:  2004-12       Impact factor: 1.600

7.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

8.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

Authors:  C G Goetz; G T Stebbins
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

Review 9.  Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease.

Authors:  David J Burn
Journal:  Mov Disord       Date:  2002-05       Impact factor: 10.338

10.  The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

Authors:  Thomas Foltynie; Carol E G Brayne; Trevor W Robbins; Roger A Barker
Journal:  Brain       Date:  2003-12-22       Impact factor: 13.501

View more
  106 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

Review 2.  Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure.

Authors:  Marc R Bothe; Ingo Uttner; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2010-01-30       Impact factor: 3.575

Review 3.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

4.  Behavioural and psychological symptoms of dementia associated with Parkinson's disease.

Authors:  I Leroi; A Burns
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-05       Impact factor: 10.154

5.  Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.

Authors:  Mariachiara Sensi; F Preda; L Trevisani; E Contini; D Gragnaniello; J G Capone; E Sette; N Golfre-Andreasi; V Tugnoli; M R Tola; R Quatrale
Journal:  J Neural Transm (Vienna)       Date:  2014-01-08       Impact factor: 3.575

Review 6.  Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Authors:  Thomas N Chase
Journal:  Neurotox Res       Date:  2010-05-15       Impact factor: 3.911

Review 7.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

8.  Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson's disease without dementia.

Authors:  Yoon-Sang Oh; Jean Hee Kim; Sang-Won Yoo; Eo-Jin Hwang; Chul Hyoung Lyoo; Kwang-Soo Lee; Joong-Seok Kim
Journal:  Neurol Sci       Date:  2020-10-31       Impact factor: 3.307

9.  Predictors of caregiver burden in partners of patients with Parkinson's disease.

Authors:  Marco D'Amelio; Valeria Terruso; Barbara Palmeri; Norma Di Benedetto; Giorgia Famoso; Paolo Cottone; Paolo Aridon; Paolo Ragonese; Giovanni Savettieri
Journal:  Neurol Sci       Date:  2009-02-03       Impact factor: 3.307

10.  Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.

Authors:  Daniel Ecker; Alexander Unrath; Jan Kassubek; Michael Sabolek
Journal:  BMC Neurol       Date:  2009-06-10       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.